HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.

By BioPharma Dive · Jun 8, 2026 · via BioPharma Dive
City banks nearly $100M for next-gen RNAi drugs

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The Oral GLP-1 Tracker: Novo's oral Wegovy hits 3M prescription milestone as Lilly's Foundayo chugs along in early launch
The WeekFiercePharma ↗
The Oral GLP-1 Tracker: Novo's oral Wegovy hits 3M prescription milestone as Lilly's Foundayo chugs along in early launch
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts' notes and IQVIA data to monitor…
Jun 9, 2026
Bial bails after Parkinson's fail, axing asset over phase 2 miss
The WeekFierceBiotech ↗
Bial bails after Parkinson's fail, axing asset over phase 2 miss
Bial has stopped development in a subpopulation of Parkinson's disease patients after its phase 2b trial misse…
Jun 9, 2026
ResMed buys Noctrix Health for $340M, widening its sleep-tech reach
The WeekBriefing
ResMed buys Noctrix Health for $340M, widening its sleep-tech reach
The sleep and respiratory giant completed the $340M Noctrix acquisition, adding a wearable neuromodulation tre…
Jun 9, 2026